Mark Larché is Reader in Respiratory Immunology at Imperial College London, Honorary Reader at the Royal Brompton Hospital and Asthma UK Senior Research Fellow. In 2004 he was a Distinguished Visiting Professor at the University of Manitoba, Canada. He is currently a member of the Medical Research Council New Investigator Awards (NIA) Panel, the MRC College of Experts (Physiological Systems and Clinical Sciences Board) and the Asthma UK Research Committee. He was Chairman of the Asthma Section of the European Academy of Allergology and Clinical Immunology (EAACI) from 2001-2005, a member of the EAACI Executive Committee (2001-2005) and is currently a member of the BSI Vaccine Affinity Group Board. Larché is an Associate Editor of Respiratory Research (http://respiratory-research.com/) and a member of the editorial board of Clinical Experimental Immunology and Clinical Experimental Allergy. He is a member of numerous professional societies including the Higher Education Academy, the British Society for Immunology, the British Society of Allergy and Clinical Immunology, the European Academy of Allergology and Clinical Immunology, the American Academy of Allergy, Asthma and Immunology, the Collegium Internationale Allergologicum.

Dr. Larché completed his PhD in Immunology at the Royal Postgraduate Medical School, Hammersmith Hospital in 1990, under the supervision of Professor Mary A. Ritter. He spent 3 years in the USA at St. Jude Children’s Research Hospital, Memphis, TN as a postdoctoral fellow. On his return to the UK he joined the Immunology Department at St. Mary’s Hospital Medical School, prior to joining the faculty of the National Heart and Lung Institute which later became a Division of the Faculty of Medicine of Imperial College.

Dr. Larché has authored over 90 scientific papers and has been the recipient of several international prizes for his work including “The Respiratory 2000 International Young Investigator Award”, “The Henning Lowenstein Research Award 2000” and the "Pharmacia Allergy Research Foundation Award" in 2001. Together with Professor AB Kay, he founded “Circassia Ltd.”, a biotechnology company to develop vaccines for allergic diseases. Research interests extend beyond asthma and allergies into transplantation, coeliac disease and autoimmune diseases.